How do I install the Icsm Screen Insulin Resistance Hypogonadism skill?

Run npx skillmds@latest add dromlakhani/icsm-screen-insulin-resistance-hypogonadism in your terminal (requires Node.js), paste this page's agent-chat prompt into Claude, Cursor, or any MCP-connected agent, or download the SKILL.md file and copy it into your agent's skills directory.

Is Icsm Screen Insulin Resistance Hypogonadism safe to use?

This skill has not completed SkillMD's automated safety review yet. Independent scanners report: SkillSpector: PASS, Skill Scanner: PASS. Capability flags: docs only. SkillMD never runs a skill's scripts for you; review the SKILL.md before installing.

Which AI agents work with Icsm Screen Insulin Resistance Hypogonadism?

This skill is tagged as working with Claude Code, Claude.ai, OpenAI Codex. SKILL.md is an open format, so most agents that read a skills directory can load it too.

Is Icsm Screen Insulin Resistance Hypogonadism free to use?

Yes. Installing skills from SkillMD is free, and the skill stays under its author's original license.

Who published Icsm Screen Insulin Resistance Hypogonadism?

dromlakhani (@dromlakhani) published this skill. Their other Agent Skills are listed on their SkillMD profile.

Icsm Screen Insulin Resistance Hypogonadism by dromlakhani

Name: Icsm Screen Insulin Resistance Hypogonadism
Rating: 4.2 (5 reviews)
Author: dromlakhani

Icsm Screen Insulin Resistance Hypogonadism

This skill recommends screening men with obesity, type 2 diabetes mellitus, or metabolic syndrome for hypogonadism given the high comorbidity between these insulin‑resistant conditions and low testosterone. It is triggered when a clinician encounters a patient with obesity, diabetes, or metabolic syndrome and questions whether to check testosterone or suspects hypogonadism in this metabolic context.

dromlakhani Updated Sep 8, 2026 10 repo stars

File contents

Screen for hypogonadism in insulin resistance conditions

STEP 1 — Gather Information

Collect presence of obesity (BMI ≥30 kg/m² or waist circumference >102 cm), type 2 diabetes mellitus (known diagnosis or HbA1c ≥6.5 %), or metabolic syndrome (central obesity plus ≥2 of: raised triglycerides, reduced HDL‑C, elevated blood pressure, elevated fasting glucose). If any condition is present, proceed to Step 2; otherwise, do not screen for hypogonadism (universal screening not recommended).

STEP 2 — Rule In / Rule Out

Is obesity, type 2 diabetes, or metabolic syndrome present?

Yes → Rule in: proceed to Step 3.
No → Rule out: stop; no testosterone screening indicated.

STEP 3 — Classify or Stratify

Obtain a morning (07:00–11:00) fasting total testosterone (tT) using a reliable assay.

If tT ≥12 nmol/L (≥350 ng/dL) → Rule out hypogonadism; stop.
If tT <12 nmol/L (<350 ng/dL) → Proceed to Step 4 for confirmation.

STEP 4 — Decide

Repeat tT on a separate occasion (morning, fasting).

If repeat tT <12 nmol/L (<350 ng/dL) → Diagnose hypogonadism; discuss testosterone therapy after shared decision‑making.
If repeat tT ≥12 nmol/L (≥350 ng/dL) → Rule out hypogonadism; stop.

Clinical Guardrails / Mimics / Pitfalls

Do not perform universal screening in asymptomatic men without obesity, diabetes, or metabolic syndrome. Avoid testing during acute illness, as results may be transiently suppressed. In clear dysmetabolic states, consider measuring SHBG and albumin to calculate free testosterone if total testosterone is borderline. Do not rely solely on symptoms; biochemical confirmation on two occasions is required. Beware of overdiagnosis when using non‑fasting or non‑morning samples.

Concrete Clinical Example

A 55‑year‑old man with BMI 32 kg/m², waist circumference 110 cm, and HbA1c 7.2 % presents for routine diabetes follow‑up; the clinician wonders whether to check testosterone. Step 1 identifies obesity and type 2 diabetes present. Step 2 rules in. Step 3 yields a morning tT of 10 nmol/L (<12 nmol/L). Step 4 repeats tT at 11 nmol/L (<12 nmol/L), confirming hypogonadism; testosterone therapy is discussed after shared decision‑making.

Source: Male hypogonadism: recommendations from the Fifth International Consultation on Sexual Medicine (ICSM 2024), International Society for Sexual Medicine, 2025, DOI: 10.1093/sxmrev/qeaf036

---name: icsm-screen-insulin-resistance-hypogonadismdescription: This skill recommends screening men with obesity, type 2 diabetes mellitus, or metabolic syndrome for hypogonadism given the high comorbidity between these insulin‑resistant conditions and low testosterone. It is triggered when a clinician encounters a patient with obesity, diabetes, or metabolic syndrome and questions whether to check testosterone or suspects hypogonadism in this metabolic context.---# Screen for hypogonadism in insulin resistance conditions## STEP 1 — Gather InformationCollect presence of obesity (BMI ≥30 kg/m² or waist circumference >102 cm), type 2 diabetes mellitus (known diagnosis or HbA1c ≥6.5 %), or metabolic syndrome (central obesity plus ≥2 of: raised triglycerides, reduced HDL‑C, elevated blood pressure, elevated fasting glucose). If any condition is present, proceed to Step 2; otherwise, do not screen for hypogonadism (universal screening not recommended).## STEP 2 — Rule In / Rule OutIs obesity, type 2 diabetes, or metabolic syndrome present? - **Yes** → Rule in: proceed to Step 3. - **No** → Rule out: stop; no testosterone screening indicated.## STEP 3 — Classify or StratifyObtain a morning (07:00–11:00) fasting total testosterone (tT) using a reliable assay. - If tT ≥12 nmol/L (≥350 ng/dL) → Rule out hypogonadism; stop. - If tT <12 nmol/L (<350 ng/dL) → Proceed to Step 4 for confirmation.## STEP 4 — DecideRepeat tT on a separate occasion (morning, fasting). - If repeat tT <12 nmol/L (<350 ng/dL) → Diagnose hypogonadism; discuss testosterone therapy after shared decision‑making. - If repeat tT ≥12 nmol/L (≥350 ng/dL) → Rule out hypogonadism; stop.## Clinical Guardrails / Mimics / PitfallsDo not perform universal screening in asymptomatic men without obesity, diabetes, or metabolic syndrome. Avoid testing during acute illness, as results may be transiently suppressed. In clear dysmetabolic states, consider measuring SHBG and albumin to calculate free testosterone if total testosterone is borderline. Do not rely solely on symptoms; biochemical confirmation on two occasions is required. Beware of overdiagnosis when using non‑fasting or non‑morning samples.## Concrete Clinical ExampleA 55‑year‑old man with BMI 32 kg/m², waist circumference 110 cm, and HbA1c 7.2 % presents for routine diabetes follow‑up; the clinician wonders whether to check testosterone. Step 1 identifies obesity and type 2 diabetes present. Step 2 rules in. Step 3 yields a morning tT of 10 nmol/L (<12 nmol/L). Step 4 repeats tT at 11 nmol/L (<12 nmol/L), confirming hypogonadism; testosterone therapy is discussed after shared decision‑making.**Source:** Male hypogonadism: recommendations from the Fifth International Consultation on Sexual Medicine (ICSM 2024), International Society for Sexual Medicine, 2025, DOI: 10.1093/sxmrev/qeaf036

Frequently asked questions